Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Protagenic Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing neuropeptide-based therapeutics for stress-related neuropsychiatric and mood disorders. Its lead candidate, PT00114, targets the brain's stress response to treat conditions like depression, anxiety, PTSD, and addiction. The company emphasizes novel mechanisms, proprietary IP, and preclinical efficacy, aiming to advance clinical trials and build a pipeline of differentiated neuropsychiatric treatments.
This description was generated via AI from an annual report. Updated about 1 year ago.